{"active_ingredient":["Active Ingredients: Lidocaine Hydrochloride 3% Purpose: Anesthetic"],"dosage_and_administration":["Dosage and Administration Adults and children 2 years of age and older: Apply using a gloved hand. Swirl the applicator tip prior to removing swab from the pouch and apply to area 3-5 minutes prior to procedure not more than 4 times daily. Children under 2 years of age: consult a physician."],"drug_interactions":["DRUG INTERACTIONS Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents: Class Examples Nitrates/Nitrites nitroglycerin, nitroprusside, nitric oxide, nitrous oxide Local anesthetics benzocaine, lidocaine, bupivacaine, inepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine Antineoplastic agents cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea Antibiotics dapsone, sulfonamides, nitrofurantoin, para¬aminosalicylic acid Antimalarials chloroquine, primaquine Anticonvulsants phenytoin, sodium valproate, phenobarbital Other drugs acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine"],"drug_interactions_table":["<table width=\"100%\"><tbody><tr><td> Class</td><td> Examples</td></tr><tr><td> Nitrates/Nitrites</td><td> nitroglycerin, nitroprusside, nitric oxide, nitrous oxide</td></tr><tr><td> Local anesthetics</td><td> benzocaine, lidocaine, bupivacaine, inepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine</td></tr><tr><td> Antineoplastic agents</td><td> cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea</td></tr><tr><td> Antibiotics</td><td> dapsone, sulfonamides, nitrofurantoin, para&#xAC;aminosalicylic acid</td></tr><tr><td> Antimalarials</td><td> chloroquine, primaquine</td></tr><tr><td> Anticonvulsants</td><td> phenytoin, sodium valproate, phenobarbital</td></tr><tr><td> Other drugs</td><td> acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine</td></tr></tbody></table>"],"effective_time":"20221004","id":"ea3b2c15-c1c6-c4ea-e053-2995a90a1dae","inactive_ingredient":["Inactive Ingredients: Aqua (Deionized Water), Carbomer, Isopropyl Alcohol, Petrolatum, Polysorbate-20, Triethanolamine"],"indications_and_usage":["Usage Pain relief"],"keep_out_of_reach_of_children":["Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away."],"openfda":{},"package_label_principal_display_panel":["LIDO DOSE Carton Insert Label"],"purpose":["Purpose: Anesthetic"],"set_id":"0b3e8433-4f93-4f01-9df0-020fb6922bce","spl_product_data_elements":["Lidodose LIDOCAINE HYDROCHLORIDE WATER CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) ISOPROPYL ALCOHOL PETROLATUM POLYSORBATE 20 TRIETHANANOLAMINE PHENYLBENZIMIDAZOLE SULFONATE LIDOCAINE HYDROCHLORIDE LIDOCAINE LIDOCAINE HYDROCHLORIDE ANHYDROUS"],"spl_unclassified_section":["PATIENT COUNSELING INFORMATION Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.","Please see product insert for additional information."],"storage_and_handling":["Storage Store between 68 and 77 F (20 - 25 C), with allowed excursions between 59 and 86 F (15 - 30 C). Protect from freezing. (See USP Controlled Room Temperature)."],"version":"7","warnings":["Warning: for external use only. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue LidoDose and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. Avoid contact with eyes. Stop use and consult a physician if condition worsens, or if symptoms persist for more than 7 days or clear up and occur again within a few days. Do not use in large quantities, particularly over raw surfaces or blistered areas."]}